Australian Clinical Labs (ASX:ACL) share price on watch following profit upgrade

Let's find out why.

| More on:
Lab worker puts hands in the air and dances around

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors will be keeping a keen eye on the Australian Clinical Labs Ltd (ASX: ACL) share price today.

The extra attention comes after the company released a promising announcement earlier this morning.

Let's take a look at why the Australian Clinical Labs share price is under focus.

Profit upgrade powers Australian Clinical Labs share price

Shares in Australian Clinical Labs are poised to fly today after announcing a profit upgrade.

Earlier today, the healthcare company announced an upgrade to its expectations for the first half of  FY22.

Based on trading to date in FY22, Australian Clinical Labs upgraded its total revenue and net profit after tax (NPAT) forecasts.

For the first half of FY22, the company now expects to deliver;

  • Total revenue of between $398.1 million and $414.0 million, representing between 29.5% and 34.7% upgrade to prospectus forecast of $307.4 million.
  • NPAT of between $63.7 and $70.0 million, representing between 177.9% and 205.6% upgrade to prospectus forecast of $22.9 million.

Australian Clinical Labs noted that the continued strong demand for COVID-19 testing and the resilience of the rest of its business fuelled the upgrade.

The company noted that the new forecasts for the first half reflect continued expansion in its margins.

In addition, Australian Clinical Labs acknowledged that a reduction in COVID-19 testing in October was also assumed in the new forecasts.

More on Australian Clinical Labs

Australian Clinical Labs initially outlined its forecasts earlier this year in its full-year report for FY21.

The company's report was headlined by a 4.2% increase in revenue of $674 million.

Other highlights from Australian Clinical Labs for FY21 included;

  • Earnings before interest, tax, depreciation and amortisation (EBITDA) came in 11% ahead of forecasts at $270 million and grew 98.4% year on year.
  • Net profit after tax (NPAT) of $88.7 million which was 19.2% in front of the prospectus forecast, and 6% ahead of (previously) upgraded guidance. This is also a 659% year on year increase.
  • Decreased net debt from $93.3 million to $64.1 million
  • Cash EBITDA to operating cash flow conversion of 101.4%, with "pro forma cash flow" of $97.2 million.

Australian Clinical Labs advised that its FY21 non-COVID revenue growth was 6.3% higher than the year prior.

In addition, the company noted that non-COVID sales growth had begun to normalise.

Snapshot of the Australian Clinical Labs share price

Australian Clinical Labs completed its initial public offering (IPO) on the ASX on 14 May 2021.

Since listing, shares in the company have soared more than 36%.

At the time of writing, the Australian Clinical Labs share price is poised to open more the 4% higher after closing yesterday's session at $4.69.

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Australian Clinical Labs Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Young businesswoman sitting in kitchen and working on laptop.
Healthcare Shares

Why CSL shares could be a bargain buy at $240

Let's see what Bell Potter is saying about this blue chip.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 ASX companies that are global leaders

Numerous ASX companies have extended their reach beyond Australia to dominate in their fields.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »